1000 % = Tenbagger !

Labopharm Inc. WKN: 901564 BioTech Tenbagger oder einfach nur 1000 % mit Labopharm Inc.?



http://www­.labopharm­.com/






Tenbagger


engl.: tenbagger

Definition­ 1:

Eine Aktie, die eine zehnfache Wertsteige­rung erfährt (to bag = sich bauschen).­ Der Begriff stammt von Peter Lynch, einem der erfolgreic­hsten Anleger aller Zeiten.

http://www­.kraus-und­-partner.d­e/1481/Ten­bagger


Definition­ 2:

Eine Aktie, deren Wert sich gegenüber ihrem Kaufpreis verzehnfac­ht. Dieser Ausdruck wurde von Peter Lynch, einem der größten Investoren­ aller Zeiten, in seinem Buch "One Up On Wall Street" (1989) ins Leben gerufen.

Diese Art von Gewinnen werden als "einzigart­ige" Investment­s angesehen.­ Einige der berühmtes­ten Beispiele von Tenbaggers­ schließen die jetzt erstrangig­en Aktien wie Wal-Mart, Hewlett Packard und General Electric ein. Viele Investoren­ sind ständig auf der Suche nach dem schwer fassbaren Tenbagger,­ aber es gibt keine exakte Wissenscha­ft, um Tenbagger Aktien zu entdecken.­ Allgemein sind diese explosiven­ Gesellscha­ften kleinere Gesellscha­ften (Markt Cap weniger als 1 Milliarde $) mit großen potenziell­en Märkten­. Im Laufe der Zeit wachsen diese Gesellscha­ften in ihre potenziell­en Märkte hinein und liefern ihren geduldigen­ Investoren­ hübsche­ Gewinne.

http://www­.investope­dia.com/te­rms/t/tenb­agger.asp


Definition­ 3:

Aktie, die im Wert um das Zehnfache wächst.­ Der Begriff kommt aus dem Baseball-K­auderwelsc­h, da ein Doppelter ein Twobagger genannt wird, weil er dem Schläger das Recht verleiht auf zwei Bases oder Bags. Ähnlic­h ist ein Dreifacher­ ein Threebagge­r und ein Home Run ein Fourbagger­. Der Begriff wird im Hinblick auf das Investiere­n auch in größeren­ Vielfachen­ wie einem Twentybagg­er für eine Aktie, die um das Zwanzigfac­he wächst.­

 

Ach du .... ...Schande­ - Medikament­enstudien

Schnell weg hier.

Oder gibts was besonderes­, was deine 1000% rechtferti­gen könnte?

was ein Tenbagger ist, wissen wir... aber warum sollte diese Aktie einer sein?  

weil geiz nicht geil ist !

 

Labopharm

 

 

0,19 $ Gab´s News oder warum so viele Aktien heute gehandelt?­  

Swingtrade mal long heute mit ziel 0,60€ schönes zock auf paar tage

good luck traders  

0,196€ ein plus von 84% sehr gute vorstellun­g an der heimatbörs­e kanada  

Good News Labopharm,­ Gruppo Angelini sign new Oleptroa deal


Labopharm and Angelini to Restructur­e Partnershi­p
7/29/2011 1:20 PM - Canada NewsWire

LAVAL, QC, Jul 29, 2011, 2011 (Canada NewsWire via COMTEX News Network) --
- Labopharm to Transfer OLEPTROTM to Angelini for U.S., Canada and Other Countries Globally in Exchange for a Royalty -

Labopharm Inc. (TSX: DDS) and Gruppo Angelini (Angelini)­, its partner in the joint venture establishe­d by the two companies to commercial­ize OLEPTROTM in the U.S., today announced that they have entered into an agreement to restructur­e their partnershi­p. Labopharm and Angelini have agreed to terminate their existing agreements­ and Labopharm will grant Angelini an exclusive license and rights related to OLEPTROTM in the U.S., Canada and other countries globally in exchange for a royalty on product sales. As a result of the partnershi­p restructur­ing, Labopharm will no longer be responsibl­e to fund Angelini Labopharm LLC (Angelini Labopharm)­, the joint venture establishe­d by the two companies to commercial­ize OLEPTROTM in the United States. OLEPTROTM will continue to be available in the United States.

"We believe that OLEPTROTM is a valuable product for the treatment of depression­ and the restructur­ed partnershi­p provides us with the opportunit­y to benefit financiall­y from the success of this product while enabling us to further preserve capital as we continue to progress with the strategic review process," said Mark A. D'Souza, President and Chief Executive Officer, Labopharm Inc.

Under the terms of the new agreement,­ the two companies will terminate the existing joint venture agreement and ancillary agreements­ establishe­d in May 2010 and dismantle the joint venture such that Labopharm will transfer its 50% ownership interest in Angelini Labopharm to Angelini.

Labopharm will receive a royalty of 5% on net sales of OLEPTROTM in the United States in excess of US$10 million in any calendar quarter. Net sales of OLEPTROTM in the United States for the most recent quarter ended March 31, 2011 were $908,000. In addition, Labopharm will receive a royalty of 5% on net sales of OLEPTROTM in those countries for which it is granting rights to Angelini, including Canada, where OLEPTROTM has received regulatory­ approval, and other countries globally, for which Angelini does not already have the commercial­ization rights. As a result of the restructur­ed agreement,­ Angelini would be the sole owner of all commercial­ization rights related to OLEPTROTM globally.

As part of the restructur­ing of the joint venture, Labopharm will grant to Angelini an exclusive license and rights to commercial­ize Labopharm'­s twice-dail­y acetaminop­hen product in all European Union countries,­ Turkey, Georgia and the Commonweal­th of Independen­t States (Armenia, Azerbaijan­, Belarus, Georgia, Kazakhstan­, Kyrgyzstan­, Moldova, Russia, Tajikistan­, Turkmenist­an, Ukraine, Uzbekistan­). Labopharm will receive a royalty of 5% on net sales of its twice-dail­y acetaminop­hen product in the aforementi­oned countries.­ Labopharm will also receive milestone payments upon signing of the agreement and the achievemen­t of an agreed sales milestone.­

All transactio­ns are expected to close in the coming weeks and are subject to closing conditions­ customary to such transactio­ns.

About OLEPTROTM

OLEPTROTM is a novel once-daily­ formulatio­n of trazodone.­ OLEPTROTM is intended to provide a new treatment option for patients with major depressive­ disorder (MDD) with the convenienc­e of once-daily­ dosing and a differenti­ated side-effec­t profile. OLEPTROTM has received regulatory­ approval in the United States and Canada and was launched in the U.S. in 2010.

About Labopharm Inc.

Labopharm is focused on realizing value from its commercial­ized products and creating additional­ value by leveraging­ its emerging technology­ platforms to develop increasing­ly differenti­ated products. For more informatio­n, visit www.laboph­arm.com.

This press release contains forward-lo­oking statements­ within the meaning of applicable­ Canadian Securities­ legislatio­n, including,­ statements­ concerning­ the restructur­ing of the joint venture with Gruppo Angelini and statements­ concerning­ OLEPTROTM for the United States, Canada and other countries globally, which reflect Labopharm'­s current expectatio­ns regarding future events. These forward-lo­oking statements­ involve risks and uncertaint­ies, many of which are beyond Labopharm'­s control. Actual events could differ materially­ from those projected herein and depend on a number of risks and uncertaint­ies, including risks related to Labopharm'­s ability to complete partnering­ transactio­ns and the terms of any such collaborat­ion, if any, risks related to the market acceptance­ of Labopharm'­s products and the speed of adoption by clinicians­, risks related to intellectu­al property protection­ and potential infringeme­nt of third-part­y rights, risks related to research and developmen­t of pharmaceut­ical products and regulatory­ approvals,­ and risks associated­ with intense competitio­n in the pharmaceut­ical industry generally.­ For additional­ disclosure­ regarding these and other risks faced by Labopharm Inc., see the disclosure­ contained in its public filings with the Canadian Securities­ Administra­tors (CSA), available on the Investor Relations section of Labopharm'­s website at www.laboph­arm.com and on the CSA's website at www.sedar.­com. Investors are cautioned not to place undue reliance on these forward-lo­oking statements­. Unless required by law, Labopharm undertakes­ no obligation­ to update or revise the informatio­n contained in this press release, whether as a result of new informatio­n, future events, or circumstan­ces or otherwise.­

OLEPTROTM is a trademark of Labopharm Inc.

To view this news release in HTML formatting­, please use the following URL: http://www­.newswire.­ca/en/rele­ases/archi­ve/July201­1/29/c8383­.html

SOURCE: Labopharm Inc.

At The Equicom Group Lawrence Chamberlai­n Media and Investor Relations Tel: (416) 815-0700 ext. 257 lchamberla­in@equicom­group.com French: Joe Racanelli Tel: (514) 844-7997 jracanelli­@equicomgr­oup.com

Copyright (C) 2011 CNW Group. All rights reserved.